--:--:--
Stockwatch Reports
…

Coverage / Healthcare / ALNY

Next Report: SITE
ALNYAlnylam Pharmaceuticals, Inc.

NasdaqGS · Healthcare · Mkt cap $31.5B · Avg vol 1.82M

$165.04

+8.39 (+5.36%)

Quote as of November 15, 2026, 4:05 PM ET

Initiating coverage · Published October 1, 2026, 11:36 AM ET

RNAi Platform Leader Navigating a Post-Peak Transition

Share
$458.12$357.39$256.67$155.94Initiated · $233.81Nov 17Mar 23Jul 20Nov 15

Quote as of November 15, 2026, 4:05 PM ET

Company overview

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a commercial-stage biopharmaceutical company focused on RNA interference (RNAi) therapeutics. The company discovers, develops, and commercializes medicines that silence specific genes responsible for disease.

How it makes money: Revenue derives primarily from product sales of approved RNAi therapeutics, supplemented by collaboration and licensing arrangements with larger pharmaceutical partners. The $5.75 EPS and implied ~$769M net income indicate the commercial portfolio has reached a scale where the company generates positive earnings.

Customers: End customers are patients and, indirectly, payers (insurers, government health programs) across the U.S., Europe, and other markets. Distribution flows through specialty pharmacies, hospitals, and infusion centers.

Scale: With 133.81M shares outstanding, a $31.5B market cap, and a beta of 0.30, Alnylam is a large-cap biotech with an unusually low correlation to broad market moves — consistent with a company whose value is driven by clinical and regulatory catalysts rather than macro cycles.

Growth outlook

Near-term (12–24 months):

  • Label expansion of existing products into additional indications, which leverages existing commercial infrastructure and carries lower incremental cost.
  • Geographic penetration, particularly in Europe and Japan, where reimbursement decisions can unlock revenue with minimal added R&D.
  • Earnings durability, the single most important near-term variable given the $5.75 EPS base and the market's evident skepticism (7.16% short interest).

Medium-term (3–5 years):

  • Pipeline readouts from earlier-stage programs, each representing a potential new revenue stream.
  • Platform partnerships, where licensing deals with large pharma can provide milestone payments and royalties with limited cost.
  • Manufacturing scale efficiencies that could support margin expansion if volumes grow.

The key risk to the growth outlook is that the current earnings level represents a peak rather than a base — a concern the market's 53% drawdown appears to reflect.

Financial analysis

Metric Historical (Trailing) Near-Term Projection Medium-Term Projection
Revenue Implied by $5.75 EPS base Moderate growth Diversified across products
Net Income ~$769M (implied) Dependent on margin durability Dependent on pipeline conversion
EPS $5.75 Flat to modest growth Dependent on new approvals
P/E (at $233.81) ~41x Compression if growth stalls Re-rating if pipeline delivers
Shares Outstanding 133.81M Stable Potential dilution if capital raised

Narrative: The trailing $5.75 EPS is the anchor of the entire valuation. At $233.81, the market pays ~41x trailing earnings — a multiple that demands confidence in forward growth. The -5.24% single-day decline and the stock's position ~53% below its 52-week high suggest investors are questioning whether that confidence is warranted. The low beta (0.30) means these moves are company-specific, not market-driven, reinforcing that the debate is about Alnylam's own earnings trajectory.

Industry & competitive landscape

Market size/TAM: The RNAi and broader genetic-medicine market is large and expanding, with applications across rare diseases, cardiovascular conditions, and neurological disorders. Total addressable market across these categories runs into the tens of billions of dollars annually, though competition for specific indications is intense.

Competitive positioning: Alnylam is a pioneer in RNAi therapeutics, with a platform that includes proprietary delivery technologies (notably GalNAc conjugation) that enable targeted gene silencing. This technology leadership is its primary moat.

Named comparables:

  • Ionis Pharmaceuticals (IONS) — antisense oligonucleotide platform, direct competitor in gene-silencing modalities.
  • Arrowhead Pharmaceuticals (ARWR) — RNAi-focused, competes in similar indication spaces.
  • Amgen (AMGN) — large-cap acquirer/partner with cardiovascular assets that overlap with RNAi applications.
  • Novartis (NVS) — major pharma with genetic-medicine investments and partnership activity in the space.

Valuation

DCF discussion: A discounted cash flow analysis for Alnylam is highly sensitive to assumptions about the durability of the $5.75 EPS base. If earnings are treated as sustainable and growing at a mid-single-digit rate with a ~10% discount rate, the implied value supports the current price. If earnings are assumed to decline from a peak, the DCF output falls materially below $233.81. The wide 52-week range ($197.81–$495.55) reflects this assumption sensitivity.

Comparable-company multiples:

Company Approx. Market Cap P/E Notes
Alnylam (ALNY) $31.5B ~41x RNAi platform leader
Ionis (IONS) — — ASO platform, comparable modality
Arrowhead (ARWR) — — RNAi-focused, earlier-stage
Amgen (AMGN) — — Large-cap, diversified

Note: Precise comparable multiples are not available from the provided data set; the table is directional. Alnylam's ~41x P/E sits at a premium to diversified large-cap pharma, reflecting its platform growth profile and pipeline optionality.

Investment thesis

Pillar 1: Platform Diversification Reduces Single-Asset Risk

Alnylam is not a one-drug story. Its RNAi platform has produced multiple commercial products across distinct indications, which spreads revenue risk and allows the company to absorb a single franchise's competitive or reimbursement setback. The financial implication is a revenue base that is structurally more resilient than peers dependent on one asset, supporting a higher floor valuation even in a bear case.

Pillar 2: Profitability Is Real but Must Be Sustained

The $5.75 trailing EPS and $31.5B market cap imply a price-to-earnings ratio of roughly 41x — a premium that only holds if earnings are durable. If the current earnings base reflects a transient peak (e.g., one-time launch dynamics or favorable mix), the multiple compresses sharply. The investment case hinges on demonstrating that margins are structural, not cyclical.

Pillar 3: Sentiment and Positioning Create Asymmetry

A 53% drawdown, 7.16% short interest, and a 0.30 beta together describe a stock where expectations are already depressed. If pipeline readouts or commercial trends stabilize, the combination of short covering and multiple re-rating can produce outsized upside. Conversely, the low float (133.24M of 133.81M shares) means moves in either direction are amplified.

Pillar 4: Pipeline Optionality Is Underappreciated at Current Levels

At $233.81, the market appears to assign limited value to earlier-stage programs. Each incremental approval or positive data readout represents a call option that is not priced into the current multiple. The financial impact is non-linear: a single successful new indication can add meaningful revenue without proportional cost, given the shared manufacturing and platform infrastructure.

Risks

  • Earnings durability risk: The $5.75 EPS base may reflect peak performance; any decline would compress the ~41x multiple sharply.
  • Pipeline/clinical risk: RNAi programs face inherent clinical, regulatory, and manufacturing risks; a single failed readout can move the stock materially, as the 53% drawdown demonstrates.
  • Competitive risk: Ionis, Arrowhead, and large pharma entrants are pursuing overlapping modalities and indications, threatening market share and pricing.
  • Reimbursement/payer risk: Genetic medicines face scrutiny from payers; adverse coverage decisions can limit commercial uptake.
  • Liquidity and positioning risk: With 7.16% of float shorted and average volume of 1.82M, the stock is susceptible to sharp moves; the recent -5.24% day on below-average volume illustrates this fragility.

Build your Watchlist & Portfolio

Last price

$165.04

Log in to add ALNY to your watchlist or simulate a trade.

Log in
Low$155.94High$233.81Initiate Price$233.81

Current $165.04

Coverage Metrics

Trend Direction

Down

Coverage High

$233.81

Coverage Low

$155.94

Initiate Price

$233.81

Current Price

$165.04

P&L

-29.41%

Quote as of November 15, 2026, 4:05 PM ET

Disclosure

This report was generated automatically by an AI-based research process, for educational and informational purposes only. It may not have been reviewed by a human for accuracy, completeness, or appropriateness prior to publication.

This report was not written or reviewed by a licensed securities analyst, investment adviser, or broker-dealer, and it does not constitute investment advice, a recommendation, or a solicitation to buy or sell any security.

The rating, price target, and all financial estimates, projections, and comparisons in this report are model outputs generated from publicly available information, including market data, company filings, and news sources. They reflect known and unknown risks, uncertainties, and assumptions, and actual results may differ materially. Past performance is not indicative of future results.

Market and company data referenced in this report reflect the date the report was generated (or, for the "Current Price" figure shown separately from the report body, the most recent quote available when viewed) and may not reflect subsequent developments. StockWatch.report and its owners, employees, and contributors may hold long or short positions in any security discussed at any time.

Investing in securities involves risk, including the risk of loss of principal. You are solely responsible for your own investment decisions, and you should consult a licensed financial professional before making any investment decision based on this report. Use of this report and the Service is governed by, and subject to, our Terms and Conditions.

Key Data

Last

$233.81

Open

$248.21

Day Range

$233.53 - $251.71

P&L ($)

$-12.93

P&L (%)

-5.24%

Volume

637.27K

Previous Close

$246.74

Average Volume

1.82M

Rel. Volume

0.4×

Market Cap

$31.5B

Shares Outstanding

133.81M

Public Float

133.24M

Beta

0.30

P/E Ratio

40.95

EPS

$5.75

Short Interest

7.19M (Sep 15, 2026)

% of Float Shorted

7.16%

As of October 1, 2026, 11:35 AM ET

Get the newsletter

Every trading day at 12:30 ET, free.

Advertise here
Stockwatch Reports

Free stock market updates, top gainers & losers, and AI-generated stock analyses — updated daily. Real-time price movements, quotes, and coverage for German & U.S. stoc